Biodegradable Nanoparticles Mediated Co-delivery of Erlotinib (ELTN) and Fedratinib (FDTN) Toward the Treatment of ELTN-Resistant Non-small Cell Lung Cancer (NSCLC) via Suppression of the JAK2/STAT3 Signaling Pathway

Background: Erlotinib (ELTN)-based targeted therapy as first-line treatment for epidermal growth factor receptor (EGFR)-mutant lung cancers suffers from insufficient selectivity, side effects, and drug resistance, which poses critical challenges in the clinical setting. Acquired resistance of ELTN r...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Donglai, Zhang, Fuquan, Wang, Jinhui, He, Hua, Duan, Shanzhou, Zhu, Rongying, Chen, Chang, Yin, Lichen, Chen, Yongbing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6242943/
https://www.ncbi.nlm.nih.gov/pubmed/30483119
http://dx.doi.org/10.3389/fphar.2018.01214

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6242943/
https://www.ncbi.nlm.nih.gov/pubmed/30483119
http://dx.doi.org/10.3389/fphar.2018.01214

Ejemplares similares